DOCSLIB.ORG

For CAST® ELISA Flow CAST® Drug Allergens

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
For CAST® ELISA Flow CAST® Drug Allergens CAST® Allergens for CAST® ELISA Flow CAST® Drug Allergens A Commitment to Diagnostics A Allergen booklet Drugs Release date: 2021-08-02 BÜHLMANN CAST® ALLERGENS 2 / 44 Release date: 2021-08-02 Content - Inhalt - Contenu- Contenuto - Contenido Introduction 3 BAG2-CERY Erythromycin 26 Literature 13 BAG2-CRIF Rifampicin 26 ACE inhibitors 14 Antiseptics 27 BAG2-CRAM Ramipril 14 BAG2-CCHX Chlorhexidine 27 Analgesics 15 Beta Blockers 28 BAG2-C51 Lys-Aspirin 15 BAG2-CBIS Bisoprolol 28 BAG2-C52 Diclofenac 15 BAG2-CMET Metoprolol 28 BAG2-C53 Ibuprofen 15 Contrast Media 29 BAG2-C54 Indomethacin 16 BAG2-CIOBI Iobitridol 29 BAG2-C55 Acetaminophen 16 BAG2-CIODI Iodixanol 29 BAG2-C56 Mefenamic Acid 16 BAG2-CIOHE Iohexol 29 BAG2-C57 Phenylbutazone 17 BAG2-CIOME Iomeprol 30 BAG2-C58 Propyphenazone 17 BAG2-CIOPA Iopamidol 30 BAG2-C59 Dipyrone / Metamizole 17 BAG2-CIOPR Iopromide 30 BAG2-CNAP Naproxen 18 BAG2-CIOXA Ioxaglate 31 BAG2-C114 Salicylic acid 18 Local Anesthetics 32 BAG2-CTRA Tramadol 18 BAG2-CART Articaine 32 Antibiotics 19 BAG2-CBUP Bupivacaine 32 BAG2-C1 Penicillin G 19 BAG2-CMEP Mepivacaine 32 BAG2-C11 Benzylpenicilloyl-Polylysine (PPL) 19 BAG2-CLID Lidocaine 33 BAG2-C12 Minor Determinant Mix (MDM) 19 Myorelaxants 34 BAG2-C2 Penicillin V 20 BAG2-CATR Atracurium 34 BAG2-C3 Cephalosporin C 20 BAG2-CCAT Cis-Atracurium 34 BAG2-C31 Cefamandole 20 BAG2-CMIV Mivacurium 34 BAG2-C32 Cefazoline 21 BAG2-CPAN Pancuronium 35 BAG2-C33 Cefuroxime 21 BAG2-CPRO Propofol 35 BAG2-C34 Cefaclor 21 BAG2-CROC Rocuronium 35 BAG2-C35 Ceftriaxone 22 BAG2-CSUX Suxamethonium 36 BAG2-C36 Levofloxacin 22 BAG2-CVEC Vecuronium 36 BAG2-C61 Sulfamethoxazole 22 BAG2-CNBX Neuromuscular Blockers Mix 37 BAG2-C62 Trimethoprim 23 Proton Pump Inhibitors 38 BAG2-C75 Tetracycline 23 BAG2-COME Omeprazole 38 BAG2-C76 Doxycycline 23 BAG2-CESO Esomeprazole 38 BAG2-C81 Ciprofloxacine 24 BAG2-CPANT Pantoprazole 38 BAG2-C82 Moxifloxacin 24 BAG2-CLAN Lansoprazole 39 BAG2-C203 Ampicillin 24 Excipients BAG2-C204 Amoxicillin 25 BAG2-CPEG PEG-4000 41 BAG2-CCLA Clarithromycin 25 BAG2-CPEG2 PEG-2000 41 BAG2-CCLAX Clavulanic Acid Amox 25 BAG2-CPEG3 DMG PEG-2000 41 BAG2-CCLIN Clindamycin 26 BÜHLMANN CAST® ALLERGENS 3 / 44 Release date: 2021-08-02 Introduction Intended Use Optimal time period for stimulation tests BÜHLMANN CAST® Allergens are optimized for in vitro For optimal results, CAST® assays should be run between Basophil Activation using BÜHLMANN CAST® assays: 3 and 12 weeks after an allergic reaction to the presumed CAST® ELISA (EK-CAST) and Flow CAST® (FK-CCR). allergen [Lit.8], although specific basophil reaction is often CAST® Allergens are not included in BÜHLMANN CAST® being persistent over a longer time period. assays. They are provided upon request. Refer to the aller- Blood samples must be drawn for CAST® assays before gen list. carrying out a skin test or in vivo provocation with the presumed allergen as in vivo exposure to an allergen can Instruction for Use cause an activation of the leucocytes. The following instructions are intended for the following groups of drug allergens and mixes of them (refer to TOC Limitations page 3). A negative CAST® assay result for a specific allergen does • ACE Inhibitors not exclude potential (even serious) clinical symptoms. Individuals who developed „allergic“ reactions towards • Analgesics protein or drug allergens in the past and whose CAST® • Antibiotics assay was negative, should thus be verified with additional • Antiseptics methods like the in vivo provocation or skin test before a drug or allergen is administered. • Beta Blockers • Contrast Media Concentrations and cut-off Concentrations and cut-off of these allergen groups were Local Anesthetics • optimized regarding maximum specificity and sensitivity. • Myorelaxants Concentrations and cut-offs of individual allergens are reported in the specifications of the allergens (refer to TOC • Proton Pump Inhibitors (PPI) page 3). • Excipients For Flow CAST®, BÜHLMANN recommends the applica- CAST® drug allergens are delivered lyophilized. Before tion of the stimulation index (SI) as an additional diagnos- usage in CAST® assays, they are to be reconstituted with tic criterion. The SI is defined as the ratio of allergen test specific Stimulation Buffer: CAST® ELISA: B-CAST-STB specific basophil activation and background activation. and Flow CAST®: B-CCR-STB. Remarks: • Add 250 µL Stimulation Buffer into the vial and vortex until the lyophilized material has completely dissolved. • In order to apply allergen specific cut-offs, QC criteria published in the CAST® instructions must be fulfilled. • For some allergens we recommend an additional dilution with Stimulation Buffer (refer to the paragraph • Cut-offs should serve only as recommendations. Clini- „Additional dilutions“ in the allergen specifications). cally defined cut-offs should be established by each laboratory or through clinical studies. • E.g. an „ additional dilution” of 1:5 is carried out by adding 160 µL Stimulation Buffer to 40 µL allergen Recommendations how to use CAST® assays in the solution. diagnosis of drug allergies • For stimulation of cells, use these dilutions according The diagnosis of drug allergies is a complex matter includ- to the respective CAST® IFU. ing heterogeneous symptoms and a diverse pathophysi- ology. Thus the following recommendations should be Remark: Some individuals react positive either at high or considered when using CAST® assays in order to diagnose at low allergen concentrations, whereas others react drug allergies. These recommendations should be consid- positive over a broad range of concentration. ered only as general guidelines. Storage and Stability Unopened CAST® Allergens are to be stored at the tempera- ture specified on the label until the expiration date. Important: Reconstituted or diluted allergens must not be stored and used again! BÜHLMANN CAST® ALLERGENS 4 / 44 Release date: 2021-08-02 Clinical pictures, justifying the application of CAST® assays Direct “allergic” reactions in vivo after exposure to drugs or chemicals can either be IgE or non-IgE mediated (pseudo-allergic reactions) stimulation of effector cells (e.g. basophils, mast cells, and eosinophils). CAST® assays may serve as a model for the above mentioned reactions by which the individuals’ leucocytes are stimu- lated in vitro. As for CAST® assays pure allergens and a defined but artificial buffer system are applied, the method can only serve as a simplified model of the real in vivo conditions. CAST® assays were optimized for the detection of immediate type allergic reactions (Type I) and pseudo allergic reactions. CAST® assays are not applicable for the diagnosis of delayed type allergies (e.g. Type IV reactions). Thus, these assays should be applied only for immediate type allergic reactions, especially if one of the following symptoms is detected: • Anaphylactic or anaphylactoide reactions • Rhino conjunctivitis • Asthma bronchiale • Urticaria / Angioedema • Gastrointestinal reactions Clinical pictures that do not justify the application of CAST® assays CAST® assays should not be used for the diagnosis of T-cell mediated reactions. Based on the pathogenetical mechanism it is not recommended using CAST® assays routinely for the following patient groups: • Maculopapular and pustular exanthema • Vasculitis • Allergic contact dermatitis • Bullous exanthemas such as Stevens-Johnsons Syndrome and Lyell’s disease BÜHLMANN CAST® ALLERGENS 5 / 44 Release date: 2021-08-02 Einführung Anwendungszweck gelagert werden. Die BÜHLMANN CAST® Allergene sind optimiert für die in vitro Leukozyten Stimulation in den BÜHLMANN CAST® Tests: CAST® ELISA (EK-CAST) und Flow CAST® Wichtig: Aufgelöste oder verdünnte Allergene sollen nicht (FK-CCR). aufbewahrt und wieder verwendet werden! CAST® Allergene sind als einzelne Reagenzien erhältlich Zeitpunkt der Patientenmessung und sind kein Bestandteil der CAST® Test Kits. Der optimale Zeitraum zur Durchführung eines CAST® Tests liegt zwischen 3 und 12 Wochen nach einer aller- Gebrauchsanweisung gischen Reaktion auf ein vermutetes Allergen [Lit.8]. Dies, Die nachfolgende Anleitung gilt für die folgenden Medika- obwohl die spezifische Reaktivität der basophilen Zellen menten-Allergene sowie deren Allergengemische (siehe oft auch über einen noch längeren Zeitraum erhalten Inhaltsverzeichnis auf Seite 3): bleibt. • ACE-Hemmer (ACE Inhibitors) Die Blutproben für die CAST® Tests müssen abgenommen • Schmerzmittel (Analgesics) werden, bevor ein Hauttest oder eine in vivo Provokation mit dem verdächtigen Allergen durchgeführt wurde. Die in • Antibiotika (Antibiotics) vivo Exposition gegenüber einem Allergen kann eine • Antiseptika (Antiseptics) generelle Aktivierung der Patientenleukozyten zur Folge haben • Betablocker (Beta Blockers) Einschränkungen • Röntgenkontrastmittel (Contrast Media) Ein negatives CAST® Test Resultat für ein spezifisches • Lokalanästhetika (Local Anesthetics) Allergen schliesst die Möglichkeit einer (auch schweren) • Muskelrelaxantien (Myorelaxants) klinischen Reaktion beim Patienten nicht aus. Patienten, • Protonenpumpeninhibitoren (PPI) die früher „allergische“ Reaktionen gegenüber Protein- oder Medikamenten-Allergenen gezeigt haben und die ein • Hilfsstoffe (Excipients) negatives CAST® Test Resultat aufweisen, sollten deswe- CAST® Medikamenten-Allergene werden in getrockneter gen, wenn möglich, mit weiteren Methoden wie in vivo Form geliefert. Vor dem Gebrauch der Allergene in den Provokation oder Hauttestung getestet werden, bevor ein CAST® Tests werden diese mit dem
Load more

Recommended publications
  • The Study Programme for the Quality Management of Essential Medicines - Good Manufacturing Practical (GMP) and Inspection
    The Study Programme for the Quality Management of Essential Medicines - Good Manufacturing Practical (GMP) and Inspection - Country Reports Japan International Corporation of Welfare Services (JICWELS) Contents 1. Cambodia 1 2. Indonesia 70 3. Malaysia 91 4. Philippines 116 5. Sri Lanka 141 6. Thailand 161 The Study Programme for the Quality Management of Essential Medicines - Good Manufacturing Practical (GMP) and Inspection - Cambodia -1- KINGDOM OF CAMBODIA Nation Religion King Ministry of Health Department of Drugs and Food Country Report The Study Program on Quality Management of Essential Medicines Good Manufacturing Practice (GMP) and Inspection November 4, 2012 – November 30, 2012 Sponsored by : The Government of Japan Japan International Cooperation Agency (JICA) Department of Drugs and Food Ministry of Health, Cambodia. -2- I- COUNTRY PROFILE -3- A-Geography Cambodia is an agricultural country located in South East Asia which bordering the Gulf of Thailand, between Thailand, Vietnam, and Laos. Its approximate geographical coordinates are 13°N 105°E. Its 2,572 km border is split among Vietnam (1,228 km), Thailand (803 km) and Laos (541 km), as well as 443 km of coastline. Cambodia covers 181,035 square kilometers in the southwestern part of the Indochina, Cambodia lies completely within the tropics; its southernmost points are only slightly more than 10° above the equator. The country is bounded on the north by Thailand and by Laos, on the east and southeast by Vietnam, and on the west by the Gulf of Thailand and by Thailand. It consists of the Tonle Sap Basin and the Mekong Lowlands. To the southeast of this great basin is the Mekong Delta, which extends through Vietnam to the South China Sea.
    [Show full text]
  • Xx250 Spc 2015 Uk
    SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT XENETIX 250 (250 mgI/ml) Solution for injection. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION per ml 50 ml 100 ml 200 ml 500 ml Iobitridol (INN) 548.4 mg 27.42 g 54.84 g 109.68 g 274.2 g Iodine corresponding to 250 mg 12.5 g 25 g 50 g 125 g Excipient with known effect : Sodium (up to 3.5 mg per 100 mL). For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection. Clear, colourless to pale yellow solution 4. CLINICAL PARTICULARS 4.1. Therapeutic indications For adults and children undergoing: . whole-body CT . venography . intra-arterial digital subtraction angiography . ERP/ERCP This medicinal product is for diagnostic use only. 4.2. Posology and method of administration The dosage may vary depending on the type of examination, the age, weight, cardiac output and general condition of the patient and the technique used. Usually the same iodine concentration and volume are used as with other iodinated X-ray contrast in current use. As with all contrast media, the lowest dose necessary to obtain adequate visualisation should be used. Adequate hydration should be assured before and after administration as for other contrast media. As a guideline, the recommended dosages are as follows: Indications Recommended dosage Whole-body CT The doses of contrast medium and the rates of administration depend on the organs under investigation, the diagnostic problem and, in particular, the different scan and image-reconstruction times of the scanners in use.
    [Show full text]
  • 01012100 Pure-Bred Horses 0 0 0 0 0 01012900 Lives Horses, Except
    AR BR UY Mercosu PY applied NCM Description applied applied applied r Final Comments tariff tariff tariff tariff Offer 01012100 Pure-bred horses 0 0 0 0 0 01012900 Lives horses, except pure-bred breeding 2 2 2 2 0 01013000 Asses, pure-bred breeding 4 4 4 4 4 01019000 Asses, except pure-bred breeding 4 4 4 4 4 01022110 Purebred breeding cattle, pregnant or lactating 0 0 0 0 0 01022190 Other pure-bred cattle, for breeding 0 0 0 0 0 Other bovine animals for breeding,pregnant or 01022911 lactating 2 2 2 2 0 01022919 Other bovine animals for breeding 2 2 2 2 4 01022990 Other live catlle 2 2 2 2 0 01023110 Pure-bred breeding buffalo, pregnant or lactating 0 0 0 0 0 01023190 Other pure-bred breeding buffalo 0 0 0 0 0 Other buffalo for breeding, ex. pure-bred or 01023911 pregnant 2 2 2 2 0 Other buffalo for breeding, except pure-bred 01023919 breeding 2 2 2 2 4 01023990 Other buffalos 2 2 2 2 0 01029000 Other live animals of bovine species 0 0 0 0 0 01031000 Pure-bred breedig swines 0 0 0 0 0 01039100 Other live swine, weighing less than 50 kg 2 2 2 2 0 01039200 Other live swine, weighing 50 kg or more 2 2 2 2 0 01041011 Pure-bred breeding, pregnant or lactating, sheep 0 0 0 0 0 01041019 Other pure-bred breeding sheep 0 0 0 0 0 01041090 Others live sheep 2 2 2 2 0 01042010 Pure-bred breeding goats 0 0 0 0 0 01042090 Other live goats 2 2 2 2 0 Fowls spec.gallus domestic.w<=185g pure-bred 01051110 breeding 0 0 0 0 0 Oth.live fowls spec.gall.domest.weig.not more than 01051190 185g 2 2 2 2 0 01051200 Live turkeys, weighing not more than 185g 2 2
    [Show full text]
  • Page 1 Note: Within Nine Months from the Publication of the Mention
    Europäisches Patentamt (19) European Patent Office & Office européen des brevets (11) EP 1 411 992 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 49/04 (2006.01) A61K 49/18 (2006.01) 13.12.2006 Bulletin 2006/50 (86) International application number: (21) Application number: 02758379.8 PCT/EP2002/008183 (22) Date of filing: 23.07.2002 (87) International publication number: WO 2003/013616 (20.02.2003 Gazette 2003/08) (54) IONIC AND NON-IONIC RADIOGRAPHIC CONTRAST AGENTS FOR USE IN COMBINED X-RAY AND NUCLEAR MAGNETIC RESONANCE DIAGNOSTICS IONISCHES UND NICHT-IONISCHES RADIOGRAPHISCHES KONTRASTMITTEL ZUR VERWENDUNG IN DER KOMBINIERTEN ROENTGEN- UND KERNSPINTOMOGRAPHIEDIAGNOSTIK SUBSTANCES IONIQUES ET NON-IONIQUES DE CONTRASTE RADIOGRAPHIQUE UTILISEES POUR ETABLIR DES DIAGNOSTICS FAISANT APPEL AUX RAYONS X ET A L’IMAGERIE PAR RESONANCE MAGNETIQUE (84) Designated Contracting States: (74) Representative: Minoja, Fabrizio AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Bianchetti Bracco Minoja S.r.l. IE IT LI LU MC NL PT SE SK TR Via Plinio, 63 20129 Milano (IT) (30) Priority: 03.08.2001 IT MI20011706 (56) References cited: (43) Date of publication of application: EP-A- 0 759 785 WO-A-00/75141 28.04.2004 Bulletin 2004/18 US-A- 5 648 536 (73) Proprietor: BRACCO IMAGING S.p.A. • K HERGAN, W. DORINGER, M. LÄNGLE W.OSER: 20134 Milano (IT) "Effects of iodinated contrast agents in MR imaging" EUROPEAN JOURNAL OF (72) Inventors: RADIOLOGY, vol. 21, 1995, pages 11-17, • AIME, Silvio XP002227102 20134 Milano (IT) • K.M.
    [Show full text]
  • Harmonised Bds Suppl 20070
    ABCDEF 1 EU Harmonised Birth Dates and related Data Lock Points, Supplementary list, 7 February 2007 Innovator brand name First DLP after Proposed Active substance name (INN) (for fixed combination 30 October Firm's Name Comments EU HBD products only) 2005 2 3 Aceclofenac 19900319 20080331 Almirall / UCB 4 Aciclovir 19810610 20060630 GSK 5 Adrafinil 19810710 20060131 Cephalon 6 Aldesleukine 19890703 20051231 Novartis NL=RMS Pfizer/Schwarz 7 Alprostadil (erectile dysfunction) 19840128 20080131 Pharma UK=RMS Alprostadil (peripheral arterial 19810723 20060731 Pfizer product differs from Schwarz Pharma 8 occlusive diseases) product Alprostadil (peripheral arterial 19841128 20051128 Schwarz Pharma product differs from Pfizer product 9 occlusive diseases) 10 Atenolol + chlorthalidone Tenoretic 19970909 20080908 AstraZeneca Azelaic acid 19881027 20060102 Schering AG / Pfizer AT = RMS 11 12 Aztreonam 19840804 20060803 BMS 13 Benazepril 19891128 20071130 Novartis Benazepril + hydrochlorothiazide Cibadrex 19920519 20070531 Novartis 14 15 Bisoprolol 19860128 20070930 Merck AG Bisoprolol + hydrochlorothiazide many product names 19920130 20061103 Merck AG 16 17 Botulinum Toxin A 19960906 20061030 Allergan currently 6-monthly PSURs 18 Brimonidine 19960906 20080930 Allergan UK=RMS 19 Brimonidine + timolol Combigan 19960906 20080930 Allergan UK=RMS 20 Bromperidol 20061115 J&J 21 Brotizolam 19830515 20071231 Boehringer Ingelheim 22 Budesonide 19920430 20070430 AstraZeneca 23 Budesonide + formoterol Symbicort 20000825 20070825 AstraZeneca 24 Buflomedil
    [Show full text]
  • A General MRI-CEST Ratiometric Approach for Ph Imaging: Demonstration of in Vivo Ph Mapping with Iobitridol
    A General MRI-CEST Ratiometric Approach for pH Imaging: Demonstration of in Vivo pH Mapping with Iobitridol The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Longo, Dario L., Phillip Zhe Sun, Lorena Consolino, Filippo C. Michelotti, Fulvio Uggeri, and Silvio Aime. 2014. “A General MRI- CEST Ratiometric Approach for pH Imaging: Demonstration of in Vivo pH Mapping with Iobitridol.” Journal of the American Chemical Society 136 (41): 14333-14336. doi:10.1021/ja5059313. http:// dx.doi.org/10.1021/ja5059313. Published Version doi:10.1021/ja5059313 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:22856989 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Communication pubs.acs.org/JACS Terms of Use A General MRI-CEST Ratiometric Approach for pH Imaging: Demonstration of in Vivo pH Mapping with Iobitridol † # ‡ # § § ⊥ ∥ Dario L. Longo, , Phillip Zhe Sun, , Lorena Consolino, Filippo C. Michelotti, , Fulvio Uggeri, § and Silvio Aime*, † § Institute of Biostructures and Bioimages (CNR) c/o Molecular Biotechnology Center and Department of Molecular Biotechnology and Health Sciences, Molecular Imaging Center, University of Torino, Torino 10126, Italy ‡ Athinoula A. Martinos Center for Biomedical Imaging, MGH and Harvard Medical School, Charlestown, Massachusetts 02129, United States ∥ Bracco Research Center, Bracco Imaging SpA, Colleretto Giacosa, Torino 10010, Italy *S Supporting Information facilitating in vivo imaging. This has been achieved by ratiometric ABSTRACT: Chemical exchange saturation transfer CEST MRI of agents with multiple magnetically non-equivalent (CEST) is a novel contrast mechanism for magnetic protons, whose CEST effects, upon ratioing, constitute the resonance imaging (MRI).
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Scanned Using Fujitsu 6670 Scanner and Scandall Pro Ver 1.7 Software
    358 1998/74 MEDICINES AMENDMENT REGULATIONS 1998 THOMAS EICHELBAUM, Administrator of the Government ORDER IN COUNCIL At Wellington this 20th day of April 1998 Present: THE HON JENNY SHIPLEY PRESIDING IN COUNCIL PURSUANT to section 105 of the Medicines Act 1981, His Excellency the Administrator of the Government, acting by and with the advice and consent of the Executive Council, and on the advice of the Minister of Health tendered after consultation with the organisations and bodies that appeared to the Minister to be representative of persons likely to be substantially affected, makes the following regulations. ANALYSIS 1. Title and commencement SCHEDULE 2. New First Schedule substituted New First Schedule of Principal Regulations 3. Revocation 1998/74 Medicines Amendment Regulations 1998 359 REGULAnONS 1. Title and commencement-( 1) These regulations may be cited as the Medicines Amendment Regulations 1998, and are part of the Medicines Regulations 1984"- ("the principal regulations"). (2) These regulations come into force on 1 June 1998. 2. New First Schedule substituted-The principal regulations are amended by revoking the First Schedule, and substituting the First Schedule set out in the Schedule of these regulations. 3. Revocation-The Medicines Regulations 1984, Amendment No. 7 (S.R. 1996/367) are consequentially revoked. ·S.R. 1984/143 Amendment No.1: (Revoked by S.R. 1996/367) Amendment No.2: (Revoked by S.R. 1996/367) Amendment NO.3: S.R. 1990/221 Amendment No.4: S.R. 1991/134 Amendment NO.5: S.R. 1992/43 Amendment NO.6: S.R. 1994/299 Amendmem No.7: 5 R 1996/367 Amendment 1997: S.R.
    [Show full text]
  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices
    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Structure and Properties of X-Ray Contrast Media
    STRUCTURE AND PROPERTIES OF X-RAY CONTRAST MEDIA Optimal use of CM in radiology requires a knowl- edge of the nature and relevant properties of the available substances. This chapter describes the properties of currently used and newly developed contrast-giving agents that infuence their behav- ior in the human body, their side effects, and their practical utility. The main X-ray contrast agents in use today are insoluble barium sulfate for the diagnostic evalu- ation of the GI tract and water-soluble CM for the radiological assessment of the different vascular systems, body cavities and organs. In addition, a water-soluble CM based on tri-iodobenzene is the alternative agent of choice for oral use when bari- um sulfate is contraindicated. Barium Sulfate Barium is used in the form of the insoluble sulfate for radiography of the GI tract. If perforation is suspected, however, only water-soluble, iodinated agents (Gastrografn, Ultravist-370) can be used since the body is virtually incapable of eliminating barium sulfate once it has entered the peritoneum. Barium sulfate is available either as a powder to be prepared directly before use or as a ready-to-use suspension. For double-contrast examinations (fll- ing of the lumen with gas, coating of the wall with barium sulfate), barium sulfate is either mixed with a carbon dioxide additive, or a gas-forming agent is taken in addition. © The Author(s) 2018 20 U. Speck, X-Ray Contrast Media, https://doi.org/10.1007/978-3-662-56465-3_3 Common to all barium preparations is concentra- tion of barium sulfate which may diluted according to the needs of the examination.
    [Show full text]
  • (320 Mg I/Ml), Solution for Injection Meglumine Ioxaglate and Sodium Ioxaglate
    HEXABRIX 320 (320 mg I/mL), solution for injection Meglumine ioxaglate and sodium ioxaglate Read all of this leaflet carefully before you start using this medicine. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. In this leaflet: 1. What HEXABRIX 320, solution for injection is and what it is used for 2. What you need to know before you use HEXABRIX 320, solution for injection 3. How to use HEXABRIX 320, solution for injection 4. Possible side effects 5. How to store HEXABRIX 320, solution for injection 6. Contents of the pack and other information 1. WHAT HEXABRIX 320 IS AND WHAT IT IS USED FOR HEXABRIX 320 is a contrast agent. It belongs to the group of contrast agents used for radiological examinations. HEXABRIX 320 is used to enhance the contrast of the images obtained during these examinations, in order to improve the visualisation and delineation of certain parts of the body, such as: Certain hollow organs (opacification of body cavities), The uterus and fallopian tubes (ducts connecting the uterus to the ovaries) in female patients (hysterosalpingography), Blood vessels (angiography), Joints (arthrography), Urinary system (urography). This medicine is for diagnostic use only. 2.
    [Show full text]